Log in

Nosopharm raises EUR 2,4 million to develop a new antibiotic

The young Nosopharm pharmaceutical company said Tuesday it has raised € 2,4 million to help it develop a new class of antibiotics.

This amount was paid by investment companies Auriga Partners Kreaxi and Alto Invest "joining the historic shareholders of the company," according to a statement.

The funds raised will enable Nosopharm accelerate the preclinical development of its first antibiotic molecule NOSO-95179, which targets Enterobacteriaceae, a specific priority pathogens by WHO.

The first clinical trials in humans should start running 2019, adds the company.

Founded in Nîmes (Gard), Nosopharm comes from a collaboration with the National Institute for Agricultural Research (INRA).

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb - drapeauitalie )

  group    administrators A3P
& Project Managers

letter   newsletter A3P